Literature DB >> 9341161

Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation.

T V Byzova1, E F Plow.   

Abstract

Prothrombin activation is a pivotal event in thrombosis and hemostasis because thrombin can mediate fibrin formation and can activate and aggregate platelets. Platelet aggregation depends upon the binding of adhesive proteins to integrin alphaIIbbeta3 on the platelet surface. In the present study, a novel interface between the blood coagulation system and platelets is demonstrated by showing that 1) prothrombin binds to alphaIIbbeta3 and 2) this interaction accelerates prothrombin activation. Prothrombin bound to purified alphaIIbbeta3 in a specific, saturable, and divalent cation-dependent manner. This interaction was inhibited by certain monoclonal antibodies to alphaIIbbeta3, by the alphaIIbbeta3 ligands fibrinogen and RGD peptides, but not by thrombin or unrelated proteins. Prothrombin also interacted with alphaIIbbeta3 on resting and stimulated platelets as demonstrated by soluble ligand binding and platelet adhesion assays. Activation of prothrombin by Factor Xa alone or Factor Xa-Va was accelerated by alphaIIbbeta3, and this enhancement was blocked by a monoclonal antibody that inhibited prothrombin binding to the receptor. Taken together, these data identify a previously unrecognized linkage between platelets and the blood coagulation system that may have a significant regulatory consequence.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9341161     DOI: 10.1074/jbc.272.43.27183

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

Review 1.  Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.

Authors:  M I Furman; A L Frelinger III; A D Michelson
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

2.  Comparison of tumor and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft model.

Authors:  Bethany A Kerr; Ranko Miocinovic; Armine K Smith; Eric A Klein; Tatiana V Byzova
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

Review 3.  Comparative pharmacology of GP IIb/IIIa antagonists.

Authors:  Karsten Schrör; Artur-Aron Weber
Journal:  J Thromb Thrombolysis       Date:  2003-04       Impact factor: 2.300

Review 4.  Antiplatelet therapies for the treatment of cardiovascular disease.

Authors:  Alan D Michelson
Journal:  Nat Rev Drug Discov       Date:  2010-02       Impact factor: 84.694

5.  A novel role for platelet secretion in angiogenesis: mediating bone marrow-derived cell mobilization and homing.

Authors:  Weiyi Feng; Maria Madajka; Bethany A Kerr; Ganapati H Mahabeleshwar; Sidney W Whiteheart; Tatiana V Byzova
Journal:  Blood       Date:  2011-01-11       Impact factor: 22.113

6.  Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.

Authors:  U Klinkhardt; J Graff; D Westrup; C M Kirchmaier; H U Esslinger; H K Breddin; S Harder
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

7.  Longistatin, a plasminogen activator, is key to the availability of blood-meals for ixodid ticks.

Authors:  M Khyrul Islam; M Abdul Alim; Takeharu Miyoshi; Takeshi Hatta; Kayoko Yamaji; Yasunobu Matsumoto; Kozo Fujisaki; Naotoshi Tsuji
Journal:  PLoS Pathog       Date:  2011-03-10       Impact factor: 6.823

8.  Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice.

Authors:  Juhua Chen; Sarmishtha De; Derek S Damron; William S Chen; Nissim Hay; Tatiana V Byzova
Journal:  Blood       Date:  2004-04-22       Impact factor: 22.113

Review 9.  Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction.

Authors:  Ara M Maranian; Steven R Steinhubl
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

10.  Systemic blood coagulation activation in acute coronary syndromes.

Authors:  Anetta Undas; Konstanty Szułdrzyński; Kathleen E Brummel-Ziedins; Wiesława Tracz; Krzysztof Zmudka; Kenneth G Mann
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.